Being that MCT2 is highly expressed in the localized tumour and MCT4 in only the most aggressive tumours, this was indicative that the carcinogenic process leading to metastatic tumour may require metabolic adaptations involving specific MCT upregulation and specific subcellular localization across different stages of the disease. The gene discussed is SLC16A1; the disease is neoplasm.